SSRI or CRF antagonism partially ameliorate depressive-like behavior after adolescent social defeat

Behavioural Brain Research

Volumn 270, Issue , 2014, Pages 295-299

  Bourke, Chase H ^a   Glasper, Erica R ^b   Neigh, Gretchen N ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Adolescence; CRF; Depression; SSRI; Stress

Indexed keywords

CORTICOTROPIN RELEASING FACTOR ANTAGONIST; FLUOXETINE; GSK 876008; UNCLASSIFIED DRUG; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GSK876008; METHYLCELLULOSE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ATTENUATION; BODY MASS; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG HALF LIFE; MALE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; SOCIAL ASPECT; SOCIAL DEFEAT; SOCIAL PSYCHOLOGY; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT GAIN; AGING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; DRUG THERAPY; MENTAL STRESS; PSYCHOLOGY; SOCIAL BEHAVIOR; WISTAR RAT;

AGING; ANIMALS; BEHAVIOR, ANIMAL; DEPRESSION; FLUOXETINE; MALE; METHYLCELLULOSE; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SEROTONIN UPTAKE INHIBITORS; SOCIAL BEHAVIOR; STRESS, PSYCHOLOGICAL;

EID: 84901913314     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.05.035     Document Type: Article

References (31)

1. Kessler R.C., Avenevoli S., Ries Merikangas K. Mood disorders in children and adolescents: an epidemiologic perspective. Biol Psychiatry 2001, 49:1002-1014.
2. Pine D.S., Cohen P., Gurley D., Brook J., Ma Y. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry 1998, 55:56-64.
3. Fergusson D.M., Horwood L.J., Ridder E.M., Beautrais A.L. Subthreshold depression in adolescence and mental health outcomes in adulthood. Arch Gen Psychiatry 2005, 62:66-72.
4. March J., Silva S., Petrycki S., Curry J., Wells K., Fairbank J., et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004, 292:807-820.
5. Tao R., Calley C.S., Hart J., Mayes T.L., Nakonezny P.A., Lu H., et al. Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. Am J Psychiatry 2012, 169:381-388.
6. Weintrob N., Cohen D., Klipper-Aurbach Y., Zadik Z., Dickerman Z. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 2002, 156:696-701.
7. Sussman N., Ginsberg D.L., Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001, 62:256-260.
8. Flandreau E.I., Bourke C.H., Ressler K.J., Vale W.W., Nemeroff C.B., Owens M.J. Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala. Psychoneuroendocrinology 2013, 38:1349-1361.
9. Gibbs D.M., Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res 1983, 280:176-179.
10. Owens M.J., Knight D.L., Ritchie J.C., Nemeroff C.B. The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. I. Acute effects on HPA axis activity and corticotropin-releasing factor-containing neurons in the rat brain. J Pharmacol Exp Ther 1991, 256:787-794.
11. Ibi D., Takuma K., Koike H., Mizoguchi H., Tsuritani K., Kuwahara Y., et al. Social isolation rearing-induced impairment of the hippocampal neurogenesis is associated with deficits in spatial memory and emotion-related behaviors in juvenile mice. J Neurochem 2008, 105:921-932.
12. Von Frijtag J.C., Reijmers L.G., Van der Harst J.E., Leus I.E., Van den Bos R., Spruijt B.M. Defeat followed by individual housing results in long-term impaired reward- and cognition-related behaviours in rats. Behav Brain Res 2000, 117:137-146.
13. Bhatnagar S., Vining C., Iyer V., Kinni V. Changes in hypothalamic-pituitary-adrenal function, body temperature, body weight and food intake with repeated social stress exposure in rats. J Neuroendocrinol 2006, 18:13-24.
14. Di Fabio R., St-Denis Y., Sabbatini F.M., Andreotti D., Arban R., Bernasconi G., et al. Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists. J Med Chem 2008, 51:7370-7379.
15. Sink K.S., Chung A., Ressler K.J., Davis M., Walker D.L. Anxiogenic effects of CGRP within the BNST may be mediated by CRF acting at BNST CRFR1 receptors. Behav Brain Res 2013, 243:286-293.
16. Homberg J.R., Olivier J.D., Blom T., Arentsen T., van Brunschot C., Schipper P., et al. Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One 2011, 6:e16646.
17. Rygula R., Abumaria N., Flugge G., Fuchs E., Ruther E., Havemann-Reinecke U. Anhedonia and motivational deficits in rats: impact of chronic social stress. Behav Brain Res 2005, 162:127-134.
18. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
19. Bernal-Morales B., Contreras C.M., Cueto-Escobedo J. Acute restraint stress produces behavioral despair in weanling rats in the forced swim test. Behav Processes 2009, 82:219-222.
20. Li Y.W., Hill G., Wong H., Kelly N., Ward K., Pierdomenico M., et al. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy. J Pharmacol Exp Ther 2003, 305:86-96.
21. Goldstein D.J., Rampey A.H., Dornseif B.E., Levine L.R., Potvin J.H., Fludzinski L.A. Fluoxetine: a randomized clinical trial in the maintenance of weight loss. Obesity Res 1993, 1:92-98.
22. Rezvanian H., Hashemipour M., Kelishadi R., Tavakoli N., Poursafa P. A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity. World J Pediatr: WJP 2010, 6:317-322.
23. Serretti A., Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010, 71:1259-1272.
24. Korczak D.J., Lipman E., Morrison K., Szatmari P. Are children and adolescents with psychiatric illness at risk for increased future body weight?. A systematic review. Dev Med Child Neurol 2013, 55:980-987.
25. Vidal J., Buwalda B., Koolhaas J.M. Male Wistar rats are more susceptible to lasting social anxiety than Wild-type Groningen rats following social defeat stress during adolescence. Behav Processes 2011, 88:76-80.
26. Hollis F., Wang H., Dietz D., Gunjan A., Kabbaj M. The effects of repeated social defeat on long-term depressive-like behavior and short-term histone modifications in the hippocampus in male Sprague-Dawley rats. Psychopharmacology 2010, 211:69-77.
27. Bourke C.H., Neigh G.N. Behavioral effects of chronic adolescent stress are sustained and sexually dimorphic. Horm Behav 2011, 60:112-120.
28. Bourke C.H., Raees M.Q., Malviya S., Bradburn C.A., Binder E.B., Neigh G.N. Glucocorticoid sensitizers Bag1 and Ppid are regulated by adolescent stress in a sex-dependent manner. Psychoneuroendocrinology 2013, 38(1):84-93.
29. Lui P., Padow V.A., Franco D., Hall B.S., Park B., Klein Z.A., et al. Divergent stress-induced neuroendocrine and behavioral responses prior to puberty. Physiol Behav 2012, 107:104-111.
30. Holsboer F., Ising M. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 2008, 583:350-357.
31. Neigh G.N., Gillespie C.F., Nemeroff C.B. The neurobiological toll of child abuse and neglect and trauma, violence & abuse 2009, 10:389-410.